Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lovastatin: a new cholesterol-lowering agent.

J J Krukemyer1, R L Talbert

  • 1College of Pharmacy, Columbus, Ohio.

Pharmacotherapy
|January 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiplatelet therapy in secondary stroke prevention.

Expert opinion on pharmacotherapy·2002
Same author

A call for pharmacists to improve the care of patients with myocardial infarction.

Pharmacotherapy·2001
Same author

Lipid management by pharmacists: evidence of benefits.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2000
Same author

Thrombolytic therapy for acute myocardial infarction.

Pharmacotherapy·1998
Same author

Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.

Stroke·1998
Same author

The pharmacist's perspective on newer thrombolytic therapies for acute myocardial infarction.Introduction.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1997
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Lovastatin effectively lowers cholesterol by inhibiting a key enzyme in its production. This new drug, effective in combination with diet or other medications, significantly reduces low-density lipoprotein cholesterol (LDL-C).

Area of Science:

  • Pharmacology
  • Biochemistry
  • Cardiovascular Medicine

Background:

  • Hypercholesterolemia poses a significant risk for cardiovascular diseases.
  • Current therapies aim to reduce cholesterol levels through various mechanisms.
  • 3-hydroxy-3-methylglutaryl-coenzyme A reductase is a critical enzyme in cholesterol biosynthesis.

Purpose of the Study:

  • To evaluate the efficacy and safety of lovastatin as a novel lipid-lowering agent.
  • To elucidate the metabolic mechanisms underlying lovastatin's cholesterol-lowering effects.
  • To determine optimal dosing and identify potential adverse effects.

Main Methods:

  • Metabolic studies were conducted in healthy volunteers and patients with hypercholesterolemia.
  • The study assessed the impact of lovastatin on serum cholesterol levels, particularly low-density lipoprotein cholesterol (LDL-C).

Related Experiment Videos

  • Investigated the mechanisms involving inhibition of cholesterol biosynthesis and enhancement of LDL-C catabolism.

    • Main Results:

    • Lovastatin demonstrated significant reductions in total cholesterol and LDL-C (average >30%) when added to baseline therapy.
    • The lipid-lowering effects were more pronounced in nonfamilial hypercholesterolemia compared to familial forms.
    • Optimal dosing was identified as 20 mg twice daily.

    Conclusions:

    • Lovastatin is a potent inhibitor of cholesterol biosynthesis, offering a new therapeutic option for hypercholesterolemia.
    • Its efficacy is attributed to reduced cholesterol synthesis and increased LDL-C catabolism via LDL receptors.
    • While generally well-tolerated, potential serious adverse effects include elevated transaminase levels and lens opacities.